Vivitrol Approved Labeling Leaves Room For Broad Marketing Plan
This article was originally published in The Pink Sheet Daily
Executive Summary
Naltrexone is the first FDA-approved extended-release monthly alcohol dependence drug, Alkermes and Cephalon say.
You may also be interested in...
Alkermes To Fly Solo On Vivitrol After Cephalon’s Departure
Biotech cites need to educate physicians about long-acting injectable for alcohol dependence.
Alkermes To Fly Solo On Vivitrol After Cephalon’s Departure
Biotech cites need to educate physicians about long-acting injectable for alcohol dependence.
Cephalon Earnings Beat Consensus, But Opinion Split On Future
"Sentiment-driven" stock due for growth year, analyst tells "The Pink Sheet" DAILY